Application of next-generation sequencing in diffuse large B-cell lymphoma

被引：0
|
作者：
Wang, Yudi [1 ]
Jia, Suzhen [1 ]
Cao, Xiubo [1 ]
Ge, Shengchen [1 ]
Yu, Kang [1 ]
Chen, Yi [1 ]
机构：
[1] Wenzhou Med Univ, Dept Hematol, Affiliated Hosp 1, Wenzhou 325000, Peoples R China
来源：
PHARMACOGENOMICS | 2023年 / 24卷 / 01期
关键词：
diffuse large B-cell lymphoma; next-generation sequencing technology; non-Hodgkin lymphoma; precision medicine; OPEN-LABEL; SINGLE-ARM; NCCN-IPI; SUBTYPES; PATHOGENESIS; MULTICENTER; EXPRESSION; INHIBITOR; DIAGNOSIS; EFFICACY;
D O I：
10.2217/pgs-2022-0140
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of invasive non-Hodgkin lymphoma. There is great heterogeneity in its molecular biological characteristics, clinical manifestations and prognosis. The use of rituximab has greatly improved the cure rate of DLBCL, but there are still 30% of patients with poor prognosis. In the era of precision medicine, the significance of molecular biology and genetic factors on the diagnosis, treatment and prognosis of patients has been found. Among these, next-generation sequencing technology plays an important role. This paper reviews the research progress of next-generation sequencing technology in the classification, diagnosis, prognosis and molecular targeted therapy of DLBCL.
引用
收藏
页码：59 / 68
页数：10
相关论文
共 50 条
  • [41] Diffuse Large B-Cell Lymphoma
    Friedberg, Jonathan W.
    Fisher, Richard I.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2008, 22 (05) : 941 - +
  • [42] Diffuse large B-cell lymphoma
    Shahi, Parham Khosravi
    Manga, Gumersindo Perez
    MEDICINA CLINICA, 2006, 127 (01): : 17 - 21
  • [43] Diffuse large B-cell lymphoma
    Alcantara, Marion
    Huynh, Tony
    HEMATOLOGIE, 2016, 22 (02): : 159 - 166
  • [44] Next-generation ALK inhibitors are highly active in ALK-positive large B-cell lymphoma
    Soumerai, Jacob D.
    Rosenthal, Allison
    Harkins, Shannon
    Duffy, Jessica
    Mecca, Carmen
    Wang, Yingbing
    Grewal, Ravinder K.
    El-Jawahri, Areej R.
    Liu, Huiyun
    Menard, Cedric
    Dogan, Ahmet
    Yang, Lei
    Rimsza, Lisa M.
    Bantilan, Kurt
    Martin, Haley
    Lei, Matthew
    Mohr, Sydney
    Kurilovich, Anna
    Kudryashova, Olga
    Postovalova, Ekaterina
    Nardi, Valentina
    Abramson, Jeremy S.
    Chiarle, Roberto
    Zelenetz, Andrew D.
    Louissaint Jr, Abner
    BLOOD, 2022, 140 (16) : 1822 - 1826
  • [45] Next-Generation Sequencing for Multiplexed Detection of B-Cell Lymphoma-Specific Mutations and IgH Clonality Assessment
    Metts, C. L.
    Schmidt, J.
    Pyfrom, S.
    Lockwood, C.
    Payton, J.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2015, 17 (06): : 804 - 805
  • [46] HASHCLONE: A NEW BIOINFORMATICS SUITE TO QUANTIFY MINIMAL RESIDUAL DISEASE BY NEXT-GENERATION SEQUENCING IN B-CELL LYMPHOMA
    Genuardi, E.
    Beccuti, M.
    Romano, G.
    Monitillo, L.
    Barbero, D.
    Furia, F.
    Calogero, R.
    Boccadoro, M.
    Ladetto, M.
    Cordero, F.
    Ferrero, S.
    HAEMATOLOGICA, 2017, 102 : 52 - 53
  • [47] Late relapses in diffuse large B-cell lymphoma: where to move next?
    Nijland, Marcel
    Kluin-Nelemans, Hanneke C.
    LEUKEMIA & LYMPHOMA, 2020, 61 (05) : 1005 - 1006
  • [48] Cutaneous diffuse large B-cell lymphoma, leg type, secondary to testicular diffuse large B-cell lymphoma
    Pampin, A.
    Gomez-de la Fuente, E.
    Feltes, R. A.
    Pinedo, F.
    Rodriguez-Peralto, J. L.
    Lopez-Estebaranz, J. L.
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2014, 39 (02) : 230 - 232
  • [49] Next-generation Sequencing Discoveries in Lymphoma
    Slack, Graham W.
    Gascoyne, Randy D.
    ADVANCES IN ANATOMIC PATHOLOGY, 2013, 20 (02) : 110 - 116
  • [50] Unclassifiable B-cell lymphoma: Between diffuse large B-cell lymphoma and Burkitt lymphoma
    Mandi, Y.
    Malihy, A.
    Kettani, F.
    Alaammari, I.
    Khmou, M.
    Touri, S.
    Rouas, L.
    Lamalmi, N.
    El Khorassani, M.
    Alhamany, Z.
    ARCHIVES DE PEDIATRIE, 2015, 22 (06): : 661 - 664
12345